Welcome to our dedicated page for Esperion Therapeutics news (Ticker: ESPR), a resource for investors and traders seeking the latest updates and insights on Esperion Therapeutics stock.
Esperion Therapeutics, Inc. (NASDAQ: ESPR) is a leading pharmaceutical company specializing in the development and commercialization of innovative, first-in-class, oral therapies aimed at lowering low-density lipoprotein cholesterol (LDL-C). The company's flagship product, ETC-1002, is a potent inhibitor of ATP citrate lyase, an enzyme integral to the cholesterol biosynthesis pathway. This pathway also includes HMG-CoA reductase, the enzyme targeted by statins.
Esperion has made significant progress with ETC-1002, completing Phase 1 and Phase 2 clinical trials, and is set to initiate Phase 3 trials. The company's product lineup includes NEXLETOL and NEXLIZET, both of which are oral, once-daily, non-statin medications designed to tackle elevated LDL-C levels. These drugs have recently received expanded FDA approval for cardiovascular risk reduction and are indicated for both primary and secondary prevention patients.
In recent news, Esperion announced that both NEXLETOL and NEXLIZET have received broad new label expansions. These labels now cover cardiovascular risk reduction and expanded LDL-C lowering, either alone or in combination with statins. This approval allows over 70 million patients to access these life-saving drugs, positioning them as the non-statin drugs of choice for cardiovascular risk management.
Esperion is also ramping up its marketing and promotional efforts, enhancing patient support programs, and working with payers to improve patient access. The company is committed to breaking barriers in cardiovascular care and continues to focus on underserved populations, including women and Hispanic/Latinx patients, as demonstrated by their recent CLEAR Outcomes trial.
The company's forward-looking strategy includes ongoing clinical development, financial management, and expansion into new markets. Esperion's dedication to transforming cardiovascular care is evident in its robust pipeline and strategic initiatives aimed at addressing critical unmet medical needs.
Esperion reported significant progress in its CLEAR Outcomes Trial, achieving 100% of targeted MACE-4 events, with topline results expected in Q1 2023. In Q2 2022, U.S. product revenue for NEXLETOL and NEXLIZET increased by 28% year-over-year to $13.6 million, while total revenue stood at $18.8 million, reflecting a 54% decline from Q2 2021 due to a one-time payment last year. R&D expenses rose to $32.4 million, driven by trial costs, while SG&A expenses fell 36% to $29.6 million. The company reported a net loss of $66.3 million, improving loss per share to $1.05.
Esperion (NASDAQ: ESPR) announced the formation of its Scientific Advisory Board (SAB) on July 25, 2022. The board features esteemed experts in atherosclerosis and cardiovascular diseases, who will guide the company's research and development strategy. CEO Sheldon Koenig emphasized the importance of the SAB's role, especially as the CLEAR Outcomes trial results are imminent. Notable co-chairs include Peter Libby and Joanne Foody. The company aims to optimize its marketed products and pipeline assets, including an oral PCSK9 inhibitor.
Esperion (NASDAQ: ESPR) will report its second quarter 2022 financial results on August 2, 2022, before U.S. markets open. A conference call with management will commence at 8:00 a.m. ET to discuss the results and business updates. Esperion focuses on developing and commercializing innovative cholesterol-lowering therapies, including NEXLETOL® and NEXLIZET®. The live audio webcast of the call will be available on the company's investor website, with a replay accessible shortly after the call, archived for 90 days.
Esperion announced a significant real-world analysis involving over 400,000 high-risk patients for atherosclerotic cardiovascular disease (ASCVD), presented at the National Lipid Association Scientific Sessions. The study revealed that 46.9% of patients were not on any statin, with only 6.6% on under-dosed statins, highlighting a gap in guideline adherence for LDL-cholesterol therapies. Additionally, the use of non-statin lipid-lowering therapies was low at 8.1%. The findings emphasize the urgent need for increased education on appropriate lipid management treatments.
Esperion (NASDAQ: ESPR) announced that CEO Sheldon Koenig will present at the 2022 Jefferies Global Healthcare Conference on June 8, 2022, at 9:00 AM (ET). The presentation will include a webcast available on the company's website, with a replay accessible two hours after the event for 90 days. Esperion is focused on developing oral, once-daily non-statin medications aimed at lowering LDL-cholesterol, catering especially to patients with unmet needs. More details can be found on their website.
Esperion (NASDAQ: ESPR) appointed J. Martin Carroll as Chairperson of its Board of Directors, effective immediately. Mr. Carroll's extensive experience, including leadership roles at Boehringer Ingelheim and Merck, positions him to provide strategic guidance as the company prepares for the upcoming CLEAR Outcomes trial results in early 2023. This leadership change aims to strengthen Esperion's efforts in commercializing its innovative cholesterol-lowering therapies.
Esperion (NASDAQ: ESPR) announced acceptance of five abstracts for presentation at the National Lipid Association Scientific Sessions 2022, highlighting research on bempedoic acid for patients with atherosclerotic cardiovascular disease and various metabolic conditions. CEO Sheldon Koenig emphasized the need for effective cholesterol management post-pandemic. The studies cover efficacy and safety details of bempedoic acid, particularly in patients with renal impairment and metabolic syndrome. The company aims to address significant public health gaps in cardiovascular care.
Esperion (NASDAQ: ESPR) announced that President and CEO Sheldon Koenig will participate in a fireside chat at the H.C. Wainwright Global Investment Conference on May 24, 2022. The event will feature a presentation and one-on-one meetings, starting at 7:00 am Eastern Standard Time. A live audio webcast will be accessible on the company’s website, with a replay available after the event. Esperion specializes in innovative cholesterol-lowering therapies, focusing on oral, once-daily non-statin medications for patients with high LDL-cholesterol levels.
Esperion (NASDAQ: ESPR) reported a strong start in Q1 2022, with total revenue of $18.8 million, a 135% increase year-over-year. U.S. product revenue for NEXLETOL and NEXLIZET surged approximately 109% to $13.4 million. Retail prescription equivalents grew 56.7%. The CLEAR Outcomes Trial is nearing 95% MACE accumulation, with expectations for a topline readout in Q1 2023. Despite a net loss of $56.7 million, significantly reduced from $90.9 million in Q1 2021, the company maintains a solid financial outlook with $268.5 million in cash reserves.
Esperion (NASDAQ: ESPR) announced the publication of data from the CLEAR Harmony Open-Label Extension Study on bempedoic acid, demonstrating its long-term safety and efficacy in lowering LDL-C levels over 2.5 years. The study followed 1,462 patients, with results indicating sustained LDL-C reductions of -14.2% for previous bempedoic acid users and -15.0% for those switching from placebo. No new safety concerns emerged, although risks of hyperuricemia and tendon rupture were noted. Bempedoic acid is approved as an adjunct therapy for patients needing additional LDL-C reduction.
FAQ
What is the current stock price of Esperion Therapeutics (ESPR)?
What is the market cap of Esperion Therapeutics (ESPR)?
What is Esperion Therapeutics, Inc.?
What products does Esperion offer?
What recent achievements has Esperion made?
What is ETC-1002?
What is the significance of the CLEAR Outcomes trial?
Who can benefit from Esperion's medications?
What partnerships does Esperion have?
What are the common side effects of NEXLETOL and NEXLIZET?
How does Esperion support its patients?
What are Esperion's future plans?
